PepGen Reports Data From Phase 1 Trial Of PGN-EDO51 For Treatment Of Duchenne Muscular Dystrophy
PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping